Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.74 |
| ▸ | CNR2 | P34972 | 9/20 | 0.74 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178271 | 1.00 | CNR1 (0.74) | CNR1CNR2HTR3AKDM4EMAPK14 | |
| SCHEMBL25368839 | 0.90 | CNR1 (0.74) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL25368841 | 0.90 | CNR1 (0.74) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL30446074 | 0.85 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL17600563 | 0.85 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL29361630 | 0.85 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL31052997 | 0.85 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL16201697 | 0.84 | CNR1 (0.94) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL25367435 | 0.83 | CNR1 (0.85) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL25367439 | 0.83 | CNR1 (0.85) | CNR1CNR2HTR3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | claimed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | claimed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CNR1 1/4885CNR2 2/4885HTR3A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.